TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from COSMO Pharmaceuticals N.V. ( (CH:COPN) ).
Cosmo Pharmaceuticals N.V. has received CE certification for its ColonPRO EU, an advanced AI software platform for colonoscopy, marking a significant milestone in its expansion into the European market. This certification, following FDA approval in the U.S., underscores Cosmo’s leadership in AI-assisted endoscopy and its commitment to innovation in colorectal cancer prevention, enhancing the company’s market position and offering improved care standards for patients.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF77.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing. The company designs, develops, and manufactures advanced solutions to meet critical medical needs and improve the standard of care, with technologies trusted by leading global pharma and MedTech companies.
YTD Price Performance: 9.77%
Average Trading Volume: 19,915
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.14B
For an in-depth examination of COPN stock, go to TipRanks’ Overview page.